Sonoma Pharmaceu Stock Price, News & Analysis

Sonoma Pharmaceuticals, Inc. (SNOA) announces EPA approval for Nanocyn®, a hospital-grade disinfectant developed with MicroSafe Group. Utilizing patented Microcyn® technology, Nanocyn® effectively reduces infection risk on hard surfaces, killing various bacteria and viruses, including norovirus, in just 30 seconds. The product, already distributed in Europe, the Middle East, and Australia, now has the potential to enter the U.S. market. With a low toxicity profile and no special handling requirements, Nanocyn® aims to enhance infection control in high-risk environments.

Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) has launched Microdox®, a new urinary tract infection catheter and bladder rinse, in New Zealand, Australia, and South Africa. This innovative product utilizes Sonoma's patented Microcyn® Technology and is designed to treat and prevent urinary tract infections (UTIs) by effectively removing UTI-causing bacteria and biofilms. The solution is non-irritating and non-toxic, ready for immediate use through partners like Te Arai BioFarma and NuAngle. The company aims to improve patient quality of life and tackle antibiotic-resistant infections.

Sonoma Pharmaceuticals (SNOA) reported a 41% decline in revenue for Q3 2021, totaling $2.9 million, due to the termination of its low-margin contract with Invekra. Despite this, gross profit improved to 41% of revenues, up 1% year-over-year and 8% sequentially. The company reported a net loss of $(944,000) compared to $(626,000) in the prior year. Total operating expenses rose slightly by 1%. Cash reserves increased to $8.5 million, indicating a strengthened balance sheet.

Sonoma Pharmaceuticals (SNOA) has expanded its U.S. distribution network by partnering with Salus Medical for the distribution of Endocyn® root canal irrigant and Microcyn® products. Additionally, Sonoma entered a partnership with Anlicare International to distribute its oral and dental care products in China, where Anlicare will manage regulatory costs for exclusive distribution rights. Sonoma's Microcyn technology offers advanced antimicrobial properties for a variety of applications, enhancing its market presence in dental care.

Sonoma Pharmaceuticals, Inc. (SNOA) announces its participation in the H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Amy Trombly and CFO Jerry Dvonch will present the company's business overview. Institutional investors can register for the virtual event through the provided link. Sonoma specializes in developing stabilized hypochlorous acid (HOCl) products for various healthcare applications, reducing infections and promoting healing. The company operates globally, distributing products in 54 countries.

Sonoma Pharmaceuticals (SNOA) reported its Q2 2021 financial results, showing revenues of $3.74 million, a 35% decline year-over-year, but a 2% increase from the previous quarter. The net loss improved to $(95,000) from $(1.1 million) in Q1. Gross profit was $1.24 million, a 33% margin, down from 43% a year ago. Operating expenses decreased by 5% year-over-year. The company raised $7.2 million through stock sales to support new product launches. Cash reserves stood at $8.4 million, indicating a strengthened balance sheet.

Sonoma Pharmaceuticals, Inc. (SNOA) and Dyamed Biotech Pte Ltd. announced an expanded partnership in Southeast Asia to enhance the reach of Sonoma's Microcyn® Technology. This partnership will cover Singapore, Malaysia, Indonesia, and Thailand, facilitating the introduction of several products including Dermacyn® for wound care, Ocucyn® for eye care, and Oracyn® for oral care. Dyamed plans new product launches in 2022, highlighting successful hospital usage in Singapore and Malaysia.

Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) and its partner MicroSafe Group announced that the Australian Therapeutic Goods Administration (TGA) has approved extended claims for their product, Nanocyn^® Disinfectant and Sanitizer. This product kills common viruses, including SARS-CoV-2 and Norovirus, within 15 seconds, and common bacteria like MRSA and E. coli within 30 seconds. Nanocyn^® is non-toxic and certified for aircraft use. The company aims to expand its international distribution network while promoting its patented Microcyn^® Technology for various healthcare applications.

Sonoma Pharmaceuticals, Inc. (SNOA) has launched three products—Regenacyn Advanced Scar Gel, Ocucyn Eyelid & Eyelash Cleanser, and MucoClyns—on Amazon for consumer purchase. These products utilize Sonoma's patented Microcyn technology and were previously available only through prescriptions. Regenacyn is clinically proven to improve scars, while Ocucyn addresses eyelid hygiene. MucoClyns serves as a personal decontamination solution. This OTC launch aims to enhance product accessibility and broaden consumer reach, reinforcing Sonoma's position in the healthcare market.